In this issue of Heart Failure Clinics, guest editors Drs. Giuseppe Limongelli, Michele Emdin, Marco Merlo, and Claudio Rapezzi bring their considerable expertise to the topic of Amyloid Cardiomyopathies: Clinical, Diagnostic and Therapeutic Aspects. Top experts in the field discuss the role of clinical use of biomarkers in cardiac amyloidosis; cardiac magnetic resonance in the management of cardiac amyloidosis; bone scintigraphy: strength points and pitfalls in the diagnosis of ATTR-cardiac amyloidosis; PET and cardiac amyloidosis; endomyocardial biopsy in the diagnosis of cardiac amyloidosis; and much more.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. x 7. Preface - p. xi 8. Amyloidosis and Amyloidogenesis: One Name, Many Diseases - p. 249 9. Pathophysiology of Cardiac Amyloidosis - p. 261 10. The Role of Echocardiography for the Clinical Diagnosis, Risk Stratification, and Management of Cardiac Amyloidosis - p. 271 11. Clinical Use of Biomarkers in Cardiac Amyloidosis - p. 283 12. Cardiovascular Magnetic Resonance in the Management of Cardiac Amyloidosis: Current and Future Clinical Applications - p. 295 13. The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis - p. 307 14. Genotype-Phenotype Correlations in ATTR Amyloidosis: A Clinical Update - p. 317 15. Standard Therapy in Cardiac Amyloidosis: What is Known, What is “Gray” - p. 325 16. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones - p. 333 17. Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis - p. 343
In this issue of Heart Failure Clinics, guest editors Drs. Giuseppe Limongelli, Michele Emdin, Marco Merlo, and Claudio Rapezzi bring their considerable expertise to the topic of Amyloid Cardiomyopathies: Clinical, Diagnostic and Therapeutic Aspects. Top experts in the field discuss the role of clinical use of biomarkers in cardiac amyloidosis; cardiac magnetic resonance in the management of cardiac amyloidosis; bone scintigraphy: strength points and pitfalls in the diagnosis of ATTR-cardiac amyloidosis; PET and cardiac amyloidosis; endomyocardial biopsy in the diagnosis of cardiac amyloidosis; and much more.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. x 7. Preface - p. xi 8. Amyloidosis and Amyloidogenesis: One Name, Many Diseases - p. 249 9. Pathophysiology of Cardiac Amyloidosis - p. 261 10. The Role of Echocardiography for the Clinical Diagnosis, Risk Stratification, and Management of Cardiac Amyloidosis - p. 271 11. Clinical Use of Biomarkers in Cardiac Amyloidosis - p. 283 12. Cardiovascular Magnetic Resonance in the Management of Cardiac Amyloidosis: Current and Future Clinical Applications - p. 295 13. The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis - p. 307 14. Genotype-Phenotype Correlations in ATTR Amyloidosis: A Clinical Update - p. 317 15. Standard Therapy in Cardiac Amyloidosis: What is Known, What is “Gray” - p. 325 16. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones - p. 333 17. Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis - p. 343
